{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:02Z","timestamp":1777420802861,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T00:00:00Z","timestamp":1403049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                    To review the literature evaluating antiretroviral-related alopecia and to provide guidance on the differential diagnosis and management of this condition.\n                    <jats:bold>Data Sources:<\/jats:bold>\n                    A literature search was performed using PubMed, MEDLINE, Embase, International Pharmaceutical Abstracts (IPA), Cumulative Index to Nursing and Allied Health (CINAHL), and the Cochrane database (through May 2014). Relevant conference abstracts and product monographs were reviewed. Search terms included\n                    <jats:italic toggle=\"yes\">antiretroviral, individual antiretroviral<\/jats:italic>\n                    classes and\n                    <jats:italic toggle=\"yes\">names, highly active antiretroviral therapy, HIV, AIDS, alopecia, hair, hair loss<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">drug<\/jats:italic>\n                    .\n                    <jats:bold>Study Selection and Data Extraction:<\/jats:bold>\n                    English-language studies and case reports were included. A total of 16 articles and 1 conference abstract were retrieved, with a total of 46 patients with hair loss.\n                    <jats:bold>Data Synthesis:<\/jats:bold>\n                    The protease inhibitor class, in particular indinavir, was most commonly reported to cause hair loss, followed by the NRTI, lamivudine. The majority of cases presented with alopecia of the scalp alone, with a median time of onset of 2.5 months. Management involved discontinuing the drug in most cases, with at least partial reversal in half the cases.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    In antiretroviral-induced alopecia, discontinuation of the suspected agent is the optimal management, and hair regrowth should occur within 1 to 3 months. Management may also include replacing the offending medication with an antiretroviral less likely to cause hair loss. It is essential to rule out other causes of alopecia with a complete patient history, including characterization of the hair loss and assessment of the patient\u2019s medical history, medication use, and family history of alopecia.\n                  <\/jats:p>","DOI":"10.1177\/1060028014540451","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T22:05:57Z","timestamp":1403129157000},"page":"1187-1193","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Antiretroviral-Related Alopecia in HIV-Infected Patients"],"prefix":"10.1177","volume":"48","author":[{"given":"Erin A.","family":"Woods","sequence":"first","affiliation":[{"name":"Hospital Pharmacy Resident. Alberta Health Services, Edmonton Zone, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Foisy","sequence":"additional","affiliation":[{"name":"Northern Alberta Program, Royal Alexandra Hospital, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,6,18]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2012.08.002"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410818."},{"key":"e_1_3_3_4_2","first-page":"292","article-title":"Cutaneous side effects induced by indinavir","volume":"10","author":"Calista D","year":"2000","unstructured":"Calista D, Boschini A. Cutaneous side effects induced by indinavir. Eur J Dermatol. 2000;10:292-296.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_3_5_2","first-page":"328","article-title":"Indinavir-related alopecia","volume":"12","author":"d\u2019Arminio Monforte A","year":"1998","unstructured":"d\u2019Arminio Monforte A, Testa L, Gianotto M, . Indinavir-related alopecia. AIDS. 1998;12:328.","journal-title":"AIDS"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200208160-00021."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462001916146."},{"key":"e_1_3_3_8_2","first-page":"742","article-title":"Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient","volume":"6","author":"Chrysos G","year":"2007","unstructured":"Chrysos G, Mikros S, Kokkoris S, Pastelli A, Kontochristopoulos G. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient. J Drugs Dermatol. 2007;6:742-743.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.5070\/D30N583197"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.8.1215."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1730-1270(10)60007-0."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281532b42."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90483-9."},{"key":"e_1_3_3_14_2","first-page":"60A","article-title":"Often mentioned, seldom seen? Severe alopecia associated with lamivudine and emtricitabine: two case reports and a review of the literature","volume":"25","author":"Grennan T","year":"2014","unstructured":"Grennan T, Koop A, Kreutzwiser D. Often mentioned, seldom seen? Severe alopecia associated with lamivudine and emtricitabine: two case reports and a review of the literature. Can J Infect Dis Med Microbiol. 2014;25(suppl A):60A.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1996.tb02919.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510025551."},{"key":"e_1_3_3_17_2","first-page":"204","article-title":"CYST, comedones and scarring alopecia: what do they have to do with HIV disease?","volume":"33","author":"El Shabrawi-Caelen LE","year":"2011","unstructured":"El Shabrawi-Caelen LE, Andre M, Kopera D. CYST, comedones and scarring alopecia: what do they have to do with HIV disease? Am J Dermatopathol. 2011;33:204.","journal-title":"Am J Dermatopathol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01240.x."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00026."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154."},{"key":"e_1_3_3_21_2","unstructured":"Shapiro J Otberg N Hordinsky M. Evaluation and diagnosis of hair loss. http:\/\/www.uptodate.com\/contents\/evaluation-and-diagnosis-of-hair-loss. Accessed October 1 2013."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2007.01.005."},{"key":"e_1_3_3_23_2","unstructured":"Reyataz (abacavir sulfate) capsule [product information]. Montr\u00e9al QC Canada: Bristol-Myers Squibb; 2013."},{"key":"e_1_3_3_24_2","unstructured":"Rescriptor (delavirdine mesylate) tablet [product information]. Montr\u00e9al QC Canada: ViiV Healthcare; 2009."},{"key":"e_1_3_3_25_2","unstructured":"Videx EC (didanosine) enteric coated beadlets capsule [product information]. Montr\u00e9al QC Canada: Bristol-Myers Squibb; 2010."},{"key":"e_1_3_3_26_2","unstructured":"Sustiva (efavirenz) capsule [product information]. Montr\u00e9al QC Canada: Bristol-Myers Squibb; 2013."},{"key":"e_1_3_3_27_2","unstructured":"Crixivan (indinavir sulfate) capsule [product information]. Kirkland QC Canada: Merck; 2012."},{"key":"e_1_3_3_28_2","unstructured":"3TC (lamivudine) tablet [product information]. Laval QC Canada: ViiV Healthcare; 2013."},{"key":"e_1_3_3_29_2","unstructured":"Kaletra (lopinavir\/ritonavir) film-coated tablet [product information]. Saint-Laurent QC Canada: AbbVie; 2012."},{"key":"e_1_3_3_30_2","unstructured":"Isentress (raltegravir potassium) tablet [product information]. Kirkland QC Canada: Merck; 2013."},{"key":"e_1_3_3_31_2","unstructured":"Norvir (ritonavir) capsule [product information]. Saint-Laurent QC Canada: AbbVie; 2012."},{"key":"e_1_3_3_32_2","unstructured":"Invirase (saquinavir mesylate) capsule [product information]. Mississauga ON Canada: Hoffmann-La Roche; 2012."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014540451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028014540451","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014540451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:15Z","timestamp":1777374915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028014540451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,18]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1177\/1060028014540451"],"URL":"https:\/\/doi.org\/10.1177\/1060028014540451","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,18]]}}}